Ropes & Gray Advises Basecamp Research on $140 Million Series C Financing

Ropes & Gray has advised Basecamp Research, a frontier AI company developing AI-designed medicines, on its oversubscribed $140 million Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development.

Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines models trained on proprietary biological data with technology for writing DNA sequences into cells. Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy – reprogramming a patient's cells inside the body.

The oversubscribed round was led by S32, with participation from Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.

The firm has previously advised Basecamp on its Series B funding round and its investment from NVIDIA in its pre-Series C round.

The Ropes & Gray team was led by venture capital & emerging companies counsel David Dowling with support from life sciences licensing partner Hannah England, venture capital & emerging companies partner Rajarshi Banerjee, associates Velyana Borisova and Iain Fox, and trainee Madeleine Matthews. Additional support was provided by litigation & enforcement partners Brendan Hanifin and Lisa Kaltenbrunner, counsel Tom Jackson, and associates Vincenzo Volpe and Mez Azizi, tax partner Andy Howard and associate Luiza Galbraith, and capital markets partner William Michener and counsel Lisa Folkerth.